FDA’s discontinued drug list: does discontinued mean unsafe?

01

What the Orange Book discontinued list means

FDA’s Orange Book includes an active prescription list and a separate cumulative discontinued list. The discontinued section can include approved products that were never marketed, are for export or military use, have stopped being marketed without an FDA safety-or-effectiveness determination, or had approvals withdrawn for reasons other than safety or effectiveness after marketing stopped.

Products generally move to the discontinued section when an applicant reports that the product is not marketed, when annual reports or other submissions indicate that status, or through another administrative action. Business decisions, manufacturing changes, replacement presentations, and other reasons may influence marketing status, but an editor should not speculate about the reason without a source.

FDA annotates products when it has published a Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. The absence of that annotation is not permission to assert the opposite; FDA notes that the set of published determinations has limits.

02

Five statuses that are easy to confuse

Approval status asks whether FDA approved the product application and whether that approval remains in force. Marketing status asks whether the applicant currently distributes it. Shortage status asks whether supply meets demand for listed presentations. Recall status concerns removal or correction of distributed product, often by lot. Withdrawal for safety or effectiveness is a specific regulatory determination about why a product left the market.

These statuses can coexist in different combinations. A product can be approved but not currently marketed. A marketed presentation can be in shortage without being discontinued. A company can recall selected lots while other lots or strengths remain available. An approval can be withdrawn for a reason unrelated to safety or effectiveness, or FDA can determine that a withdrawn product was removed for safety or effectiveness reasons.

A directory should use the narrow status supported by the record. “Not currently marketed” is safer than “banned,” and “FDA determined withdrawal was for safety reasons” is stronger than “the pharmacy no longer carries it.”

03

How to research an exact peptide product

Start with the established name and proprietary name, then capture dosage form, route, strength, applicant, and NDA or ANDA number. Search the Orange Book by ingredient or application and determine whether that exact presentation is active or discontinued. Similar strengths or delivery systems may have different records.

Open Drugs@FDA to review the application’s approval history, labeling, approval letters, and any withdrawal documents available there. Search FDA’s additions and deletions pages and the Federal Register for a product-specific safety-or-effectiveness determination. Date every result because monthly supplements and database records change.

If the practical question is availability, separately check FDA’s current shortages and discontinuations database and contact a pharmacist. Regulatory database status does not guarantee inventory at a particular pharmacy, and local unavailability does not prove national discontinuation.

• →Established and brand names
• →Route and dosage form
• →Exact strength
• →Applicant
• →Application number
• →Active or discontinued Orange Book section
• →Federal Register determination
• →Current shortage or discontinuation record

04

Why discontinued does not mean unapproved

Moving to the Orange Book’s discontinued section does not necessarily erase the underlying approval. FDA’s preface explains that the section includes several categories of approved products. The application history must be checked to determine whether approval was withdrawn and why.

This distinction matters when providers describe older peptide drugs. A discontinued presentation may still have an FDA-reviewed historical label, but that label does not approve a different compounded formulation, route, strength, or intended use. Conversely, an unapproved peptide does not become legitimate because an approved product with a similar name is no longer marketed.

Off-label prescribing of a currently approved product is another separate issue. It should not be confused with using a discontinued presentation, a compounded copy, or a research-use-only substance.

05

Provider and pharmacy claims to investigate

Be cautious when a provider says compounding is permitted simply because a brand was discontinued, unavailable locally, or expensive. Federal compounding conditions use specific standards, and a marketing-status claim does not by itself establish a patient-specific need, shortage exception, bulk-substance eligibility, or compliance with the restrictions on essentially copies.

Ask the provider to name the exact commercially available product and official status source. If it says FDA withdrew a product for safety, request the Federal Register notice or FDA page. If it says the product remains approved but discontinued, capture the application history and discontinued-list record.

Do not turn the result into clinical advice. A product’s market history does not determine whether another therapy is suitable for an individual, and a pharmacist or prescriber should address continuity-of-care questions.

06

Limits and update triggers

Orange Book and availability data change. This guide does not provide a current status for every peptide drug or predict whether a manufacturer will resume marketing. Recheck official databases on the date of publication and before relying on an availability claim.

The article should be updated when FDA changes the Orange Book preface or annotations, posts a product-specific safety determination, withdraws an approval, or changes the status of a product used as an example.